Unitarity bounds on low scale quantum gravity

We study the unitarity of models with low scale quantum gravity both in four dimensions and in models with a large extra-dimensional volume. We find that models with low scale quantum gravity have problems with unitarity below the scale at which gravity becomes strong. An important consequence of our work is that their first signal at the Large Hadron Collider would not be of a gravitational nature such as graviton emission or small black holes, but rather linked to the mechanism which fixes the unitarity problem. We also study models with scalar fields with non minimal couplings to the Ricci scalar. We consider the strength of gravity in these models and study the consequences for inflation models with non-minimally coupled scalar fields. We show that a single scalar field with a large non-minimal coupling can lower the Planck mass in the TeV region. In that model, it is possible to lower the scale at which gravity becomes strong down to 14 TeV without violating unitarity below that scale.Comment: 15 page

Quantum group symmetry and particle scattering in (2+1)-dimensional quantum gravity

Starting with the Chern-Simons formulation of (2+1)-dimensional gravity we show that the gravitational interactions deform the Poincare symmetry of flat space-time to a quantum group symmetry. The relevant quantum group is the quantum double of the universal cover of the (2+1)-dimensional Lorentz group, or Lorentz double for short. We construct the Hilbert space of two gravitating particles and use the universal R-matrix of the Lorentz double to derive a general expression for the scattering cross section of gravitating particles with spin. In appropriate limits our formula reproduces the semi-classical scattering formulae found by 't Hooft, Deser, Jackiw and de Sousa Gerbert.Comment: 45 pages, amslate

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362